Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 10 of about 13   

Articles published

DVAX 29.41 +0.19 (0.65%)
price chart
Analysts At William Blair Maintain Outperform On Dynavax Technologies
The firm points out that Dynavax has received the briefing book from the FDA by now and no news so far is good news. Moreover, Dynavax had communicated that if there were material information, the company would disclose it to the public. The firm ...
Dynavax Falls After Vaccine Fails to Win Panel Backing
Nov. 16 (Bloomberg) -- Dynavax Technologies Corp. tumbled the most in four years after its hepatitis B vaccine Heplisav failed to win the backing of U.S.
Dynavax's Heplisav Vaccine Works on Hepatitis B, FDA Says
Nov. 13 (Bloomberg) -- Dynavax Technologies Corp.'s Heplisav vaccine works against the contagious liver disease hepatitis B, Food and Drug Administration staff said.
Can Dynavax overcome Heplisav blow?
Two weeks ago, an FDA panel dealt a blow to Dynavax Technologies ($DVAX), raising concerns about the safety of the company's hepatitis B vaccine, Heplisav. Shares dropped and investors tend to turn their backs on a company when stock prices go down.
U.S. Stock Futures Retreat as Obama Holds Budget Talks
Dynavax Technologies Corp. tumbled 47 percent to $2.44 after its hepatitis B vaccine Heplisav failed to win the backing of U.S.
Facebook (FB) Is What it Is. It's a Time Waster
Facebook (FB) Is What it Is. Its a Time Waster First, I'm not recommending to any of my companies that we leave facebook. I am recommending that we de-emphasize pushing consumers or partners to like us on Facebook (FB) and focus on building up our ...
JA Solar Has to Stoop to a Reverse Stock Split
What you are about to read is a sneaky way of announcing a reverse stock split to stay within the listing standards of the $1.00 share price rule.
Dynavax to initiate phase I studies for TLR-9 agonist for asthma
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into phase I clinical studies.
Dendreon: What's The Company Worth Per Share?
The GSK-HGSI bid demonstrates even a company that was struggling the way HSGI was can attract a suitor if the technology product(s) involved are considered a prize. Remember, Human Genome had been troubled by a 69% stock decrease in 2011 (does ...
Vical's Allovectin: Update On The Phase III Trial
While the corporation would not reveal the target number of death events, the release did indicate a moving average study of the monthly event rate which caused management to revise its projection for reaching the target number to mid-2013.